Objective:
To investigate whether impaired autophagy and mitophagy contribute to mitochondrial accumulation, oxidative stress, and retinal ganglion cell (RGC) degeneration in glaucoma.
Approach:
- Models: Researchers used glucocorticoid-induced and myocilin-associated mouse glaucoma models, mitophagy reporter mice, RGC-specific genetic manipulation, and ex vivo human retinal tissue.
- Interventions and measures: They assessed mitochondrial structure, mitophagy, oxidative damage, RGC function and survival, and optic nerve axons; they also tested autophagy activation with intravitreal Torin 2.
Key Findings:
- Sustained ocular hypertension was associated with abnormal mitochondrial accumulation and oxidative DNA damage in RGCs and optic nerve axons.
- Mitophagy was reduced after five weeks of ocular hypertension, before detectable RGC loss and axonal degeneration, and remained impaired after degeneration was established.
- RGC-specific disruption of Atg5 was followed by mitochondrial abnormalities, oxidative DNA damage, impaired RGC function, approximately 39% RGC loss, and approximately 59% loss of healthy optic nerve axons.
- In the glucocorticoid-induced mouse model, Torin 2 increased mitophagy and preserved RGC function without changing IOP. Mean pattern electroretinography amplitudes were 31.82 µV in treated hypertensive eyes versus 17.36 µV in control-treated eyes; treatment was also associated with 37% more RGCs and 51% more morphologically intact axons.
- In neurotrophic factor-deprived human retinal explants, Torin 2 increased RGC survival by approximately 49.7%.
Interpretation:
The authors’ findings place impaired mitochondrial clearance before detectable RGC degeneration in the studied models and support further investigation of autophagy and mitophagy as potential neuroprotective targets.
Limitations:
- The work is preclinical.
- In the myocilin model, some neuroprotection may have resulted from an accompanying reduction in IOP.
- Torin 2 broadly inhibits mTOR, which may complicate translation; the authors propose studying more selective autophagy or mitophagy modulators.
Conclusion:
The authors state that future studies will focus on selective autophagy/mitophagy modulators or pathway-specific interventions to validate and refine mitophagy-targeted approaches for glaucoma.
Sources:
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.